UNSPSC 51314356: Citric/ipecac/phenylephrine/potassium/promethazine/sodium citrate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314356 Citric/ipecac/phenylephrine/potassium/promethazine/sodium citrate is a Commodity code that encompasses pharmaceutical active ingredients and finished pharmaceutical products sold to state and local health agencies, often through competitive bidding or cooperative purchasing frameworks. State and local governments procure these pharmaceuticals for emergency response, public health programs, and institutional health services — including naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals distributed through state facilities, and direct-to-manufacturer prescription programs designed to improve fulfillment efficiency and cost management. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance administering MMCAP).

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on establishing direct-to-manufacturer prescription relationships outside traditional pharmacy benefit manager and group purchasing organization channels. Minnesota's MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract awards effective July 1, 2026. Vendors must demonstrate cGMP compliance, Drug Supply Chain Security Act certification, relationships with authorized wholesalers, and ability to meet FDA requirements and shelf-life standards; MMCAP evaluates proposals on price competitiveness (75 percent weight), fixed pricing (10 percent), administrative fee compliance (5 percent), EDI capability (5 percent), and data format requirements (5 percent).